Tumour heterogeneity and the evolution of polyclonal drug resistanceRebecca A. Burrell, Charles Swanton|Molecular Oncology|2014Cited by 419
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trialRebecca A. Burrell, Richard D. Baird|Nature Cancer|2026Cited by 2